Hypolipidemic and antioxidant activities of pioglitazone in hyperlipidemic rats

Rama R. Bhosale, Rakesh R. Jadhav, Sudhir L. Padwal, Vinod S. Deshmukh


Background: Diabetes mellitus (DM) is an endocrine disorder characterized by abnormal carbohydrate, lipid and protein metabolism along with specific long-term complications which are associated with hyperlipidemia and oxidative stress. Hence, it is important to find hypoglycemic drug that improves lipid profile and reduces oxidative stress in diabetic patient. This study, therefore, was performed to investigate hypolipidemic and antioxidant potential of Pioglitazone (PIO) in hyperlipidemic rats.

Methods: Hyperlipidemia was induced in normal rats by including 0.75 gm% cholesterol and 1.5 gm% bile salt in normal diet and these rats were used for the experiments. PIO hydrochloride was administered as 10 mg/kg and 30 mg/kg dose levels to the hyperlipidemic rats. Hypolipidemic activity was estimated by plasma lipid profile parameters while antioxidant potential was estimated by ascorbic acid, catalase activity, malondialdehyde and superoxide dismutase activity using standard methods. Statistical analysis was done by one way analysis of variance (ANOVA) followed by Dunnett’s test.

Results:  Treatment with 10 mg/kg and 30 mg/kg dose levels of PIO hydrochloride resulted in a significant decrease in serum TG and VLDL only in 30 mg/kg PIO treated group and significant increase in serum HDL in both groups, but no significant decrease in cholesterol and LDL in both PIO treated groups. PIO increased activities of catalase enzyme and concentration of malondialdehyde significantly in only 30 mg/kg PIO treated group. But there were no significant changes in the superoxide dismutase activity and ascorbic acid concentration in both PIO treated groups.

Conclusions: The present study demonstrated that treatment with 10 mg/kg and 30 mg/kg dose levels of PIO hydrochloride improves the plasma lipid profile and also reduces oxidative stress in hyperlipidemic animals.


Antioxidant, Diabetes, Hyperlipidemia, Pioglitazone

Full Text:



Pandey A, Tripathi P, Pandey R, Srivatava R, Goswami S. Alternative therapies useful in the management of diabetes: A systematic review. J Pharm Bioallied Sci 2011;3:504-12.

Mazumder PM, Farswan M, Parcha V. Effect of an isolated active compound (Cg-1) of Cassia glauca leaf on blood glucose, lipid profile, and atherogenic index in diabetic rats. Indian J Pharmacol 2009;41:182-6.

Shanmugam KR, Mallikarjuna K, Reddy KS. Effect of alcohol on blood glucose and antioxidant enzymes in the liver and kidney of diabetic rats. Indian J Pharmacol 2011;43:330-5.

Biswas A, Rabbani SI, Devi K. Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats. Indian J Pharmacol 2012;44:333-9.

Kakadiya J, Shah NJ. Hypoglycemic and hypolipidemic activity of Pioglitazone in normal and Streptozotocin-Nicotinamide induced diabetic rats. Pharmacologyonline 2010;1:1-7.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23.

Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002;51:314-7.

Visavadiya NP, R.L. Narasimhacharya AV. Hypolipidemic and antioxidant activities of Asparagus racemosus in hypercholesteremic rats. Indian J Pharmacol 2005;37:376-80.

Roeschlau P, Bernt E, Gruber F. J Clin Chem Clin Biochem 1974;12:226.

McGowan MW, et al. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538.

Lorentz K, Flatter B, Augustin E. Arylesterase in serum: elaboration and clinical application of a fixed-incubation method. Clin Chem 1979;25:1714-20.

Chatterjee MN. Textbook of Medical Biochemistry, 7th edition. JAYPEE Brothers: New Deli, India 2007;418-20.

Schaffert RR, Kingsley GR. A rapid, simple method for the determination of reduced, dehydro-, and total ascorbic acid in biological membrane. J Bio Chem1955;212:59-68.

Cohen G. Dembiec D. Marcus J. Measurement of catalase activity in tissue extract. Anal Biochem1970;34:30-8.

Pasha KV, Sadasivadu B. Intracellular content of thiol compounds, thiobarbituric acid reactive substances and gamma-glutamyl transpeptidase in rat brain during anoxia. Neurosci Lett 1984;46:209-14.

Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-74.

Mahajan BK. Significance of difference in mean. In Methods in Biostatistics, 6th edition; 2006:130-55.

Durrington P. Dyslipidaemia. Lancet 2003;362:717-31.

Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003;54:321-41.

Singh R, Singh N, Saini BS, Rao HS. In vitro antioxidant activity of pet ether extract of black pepper. Indian J Pharmacol 2008;40:147-51.

Hsiao PJ, Hsieh TJ, Kuo KK, Hung WW, Tsai KB, et al. Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC Mol Biol 2008;9:82.

Rabbani SI, Devi K, Khanam S. Pioglitazone, a PPAR-gamma ligand inhibited the nicotinamide-streptozotocin induced sperm abnormalities in type-2 diabetic Wistar rats. Pak J Pharm Sci 2010;23:326-31.

Hasegawa T, Okada K, Okita Y, Pinsky DJ. Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. J Heart Lung Transplant 2011;30:1186-96.